Purvalanol A is a cell-permeable, potent, and selective inhibitor of cyclin-dependent kinases.
This report contains market size and forecasts of Purvalanol A(CDK Inhibitor) in global, including the following market information:
Global Purvalanol A(CDK Inhibitor) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Purvalanol A(CDK Inhibitor) Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five Purvalanol A(CDK Inhibitor) companies in 2021 (%)
The global Purvalanol A(CDK Inhibitor) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Min Purity Less Than 98% Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Purvalanol A(CDK Inhibitor) include Merck, Santa Cruz Biotechnology, BOC Sciences, Cayman Chemical, STEMCELL Technologies, Bio-Techne, Focus Biomolecules, Abcam and Enzo Biochem, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Purvalanol A(CDK Inhibitor) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Purvalanol A(CDK Inhibitor) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Purvalanol A(CDK Inhibitor) Market Segment Percentages, by Type, 2021 (%)
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Global Purvalanol A(CDK Inhibitor) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Purvalanol A(CDK Inhibitor) Market Segment Percentages, by Application, 2021 (%)
Research
Medical
Global Purvalanol A(CDK Inhibitor) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Purvalanol A(CDK Inhibitor) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Purvalanol A(CDK Inhibitor) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Purvalanol A(CDK Inhibitor) revenues share in global market, 2021 (%)
Key companies Purvalanol A(CDK Inhibitor) sales in global market, 2017-2022 (Estimated), (Kg)
Key companies Purvalanol A(CDK Inhibitor) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Santa Cruz Biotechnology
BOC Sciences
Cayman Chemical
STEMCELL Technologies
Bio-Techne
Focus Biomolecules
Abcam
Enzo Biochem
Adooq Bioscience
APExBIO Technology
United States Biological
Selleck Chemicals
Toronto Research Chemicals
CSNpharm
Biorbyt
LKT Laboratories
Beyotime